MIRM β€” MIRUM PHARMACEUTICALS INC

Ownership history in Frazier Life Sciences Management, L.P.  Β·  16 quarters on record

AI Ownership Summary

Frazier Life Sciences Management, L.P. reported MIRUM PHARMACEUTICALS INC (MIRM) in 16 quarterly 13F filings from 2023 Q3 through 2025 Q4. Peak portfolio weight reached 14.93% in 2025 Q3. The latest visible filing shows MIRM at 14.42% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this MIRM ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Frazier Life Sciences Management, L.P.'s position in MIRUM PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

MIRM was reported at 14.42% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
14.93% in 2025 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q3 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Frazier Life Sciences Management, L.P. held MIRM β€” position size vs. price
% of Fund (quarterly)    MIRM price (quarter-end, indexed to 100)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 UNCHANGED 6,795,121 β€” 0% 14.42% $536.7M 2026-02-14 (Est.) $103.10
2025 Q3 UNCHANGED 6,795,121 β€” 0% 14.93% $498.2M 2025-11-14 $71.44
2025 Q2 UNCHANGED 6,795,121 β€” 0% 13.83% $345.8M 2025-08-14 $64.83
2025 Q1 ADDED 6,795,121 +224,729 +3.4% 13.99% $306.1M 2025-05-15 $45.28
2024 Q4 UNCHANGED 6,570,392 β€” 0% 11.28% $271.7M 2025-02-18 $52.70
2024 Q3 ADDED 6,570,392 +75,000 +1.2% 10.27% $256.2M 2024-11-15 $44.50
2024 Q2 UNCHANGED 6,495,392 β€” 0% 10.39% $222.1M 2024-08-15 $41.53
2024 Q1 UNCHANGED 6,495,392 β€” 0% 6.88% $163.2M 2024-05-15 $24.99
2023 Q4 ADDED 6,495,392 +25,000 +0.4% 10.25% $191.7M 2024-02-14 $28.47
2023 Q3 ADDED 6,470,392 +2,110,285 +48.4% 13.58% $204.5M 2023-11-14 $30.33
6 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

FAQ About Frazier Life Sciences Management, L.P. and MIRM

These are the practical questions this page is built to answer before you even open the full history table.

How long has Frazier Life Sciences Management, L.P. reported owning MIRM?

Frazier Life Sciences Management, L.P. reported MIRM across 10 quarterly 13F filings, from 2023 Q3 through 2025 Q4.

What was the largest reported MIRM position in Frazier Life Sciences Management, L.P.'s portfolio?

The largest reported portfolio weight for MIRM was 14.93% in 2025 Q3.

What is the latest reported MIRM position on this page?

The most recent filing on this page is 2025 Q4, when Frazier Life Sciences Management, L.P. reported 6,795,121 shares, equal to 14.42% of portfolio, with an estimated market value of $536.7M.

What does the chart on this MIRM ownership page compare?

The chart compares Frazier Life Sciences Management, L.P.'s quarterly MIRM portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Frazier Life Sciences Management, L.P. Holdings